Abstract
The GioTag study assessed how drugs called afatinib and osimertinib affected people with non-small cell lung cancer (NSCLC) who had mutations in the epidermal growth factor receptor (EGFR) gene. Resistance mutations in our genes can lead to resistance to specific treatments, meaning that drugs no longer work. Patients in the current study all initially received afatinib treatment before they developed a certain resistance mutation in the EGFR gene, called T790M. Patients then started osimertinib treatment. The study aimed to identify for how long patients received treatment and for how long patients survived after their first dose of afatinib. Overall, 204 patients were included. Median overall time on treatment (afatinib and osimertinib) was 27.7 months. Median overall survival was 37.6 months. This study showed that afatinib followed by osimertinib treatment was effective in patients with NSCLC with EGFR mutations developing T790M resistance mutations on initial afatinib treatment.
To read the full Plain Language Summary of this article, click here to view the PDF.
Link to original article here.
Financial & competing interests disclosure
MJ Hochmair reports personal fees from Speakers honorarium Boehringer Ingelheim, AstraZeneca and Roche. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Medical writing assistance was provided by Hannah Simmons, of Ashfield MedComms, an Ashfield Health company, part of UDG Healthcare plc and was supported financially by Boehringer Ingelheim.